Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline to Help InforSense, Spotfire Co-develop Software

NEW YORK, May 17 (GenomeWeb News) - InforSense, Spotfire, and GlaxoSmithKline have begun a pilot project to co-develop software for certain data-management applications in drug discovery, the companies said today.


The alliance will lead to a product that Spotfire and InforSense will commercialize before the end of the year, a spokeswoman for Spotfire said.


The collaboration will marry Glaxo's experience building web services to scientific systems; Spotfire's knowledge of visual analytic applications; and InforSense's background in workflow-based integrative analytics, the companies said. 


The deal is meant to engage the concept of "effectively orchestrating web services, disparate data sources, and interactive end-user applications across a large enterprise," Christopher Ahlberg, CEO of Spotfire, said in a statement.


Financial details were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.